Michelle Robertson
Director of Finance/CFO bei GERON CORPORATION
Vermögen: 229 805 $ am 31.03.2024
Aktive Positionen von Michelle Robertson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VERASTEM, INC. | Director/Board Member | 15.11.2021 | - |
| Independent Dir/Board Member | 15.11.2021 | - | |
| GERON CORPORATION | Director of Finance/CFO | 25.09.2023 | - |
| Treasurer | 25.09.2023 | - |
Karriereverlauf von Michelle Robertson
Ehemalige bekannte Positionen von Michelle Robertson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EDITAS MEDICINE, INC. | Director of Finance/CFO | 09.01.2020 | 17.05.2023 |
| Treasurer | 09.01.2020 | 17.05.2023 | |
| MOMENTA PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 05.10.2018 | 08.01.2020 |
| Director of Finance/CFO | 05.10.2018 | 08.01.2020 | |
| Corporate Officer/Principal | 01.05.2017 | 05.10.2018 | |
| Treasurer | 05.10.2018 | 08.01.2020 | |
| BAXALTA INC | Corporate Officer/Principal | 01.01.2015 | 01.01.2016 |
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2012 | 01.01.2015 |
Ausbildung von Michelle Robertson
| Bentley University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| Director of Finance/CFO | 3 |
| Corporate Officer/Principal | 3 |
| Treasurer | 3 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| GERON CORPORATION | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
- Börse
- Insiders
- Michelle Robertson
- Erfahrung
